Marker Therapeutics Sells Subsidiary, Focuses on T-cell Therapies
Ticker: MRKR · Form: 8-K · Filed: Aug 12, 2024 · CIK: 1094038
| Field | Detail |
|---|---|
| Company | Marker Therapeutics, Inc. (MRKR) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $2 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: divestiture, strategic-shift, t-cell-therapy
TL;DR
Marker sold its subsidiary, focusing on T-cell therapies. Deal closes Q4 2024.
AI Summary
Marker Therapeutics, Inc. announced on August 12, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Marker Therapeutics, LLC, to a third party. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This sale is part of the company's strategic plan to focus on its T-cell therapies.
Why It Matters
This divestiture signals a strategic shift for Marker Therapeutics, potentially streamlining operations and allowing for a more concentrated effort on its core T-cell therapy development.
Risk Assessment
Risk Level: medium — The sale of a subsidiary introduces execution risk and potential impact on future revenue streams, while the focus on T-cell therapies carries inherent risks associated with drug development.
Key Numbers
- Q4 2024 — Expected Closing (Timeline for the sale of the subsidiary)
Key Players & Entities
- Marker Therapeutics, Inc. (company) — Registrant
- Marker Therapeutics, LLC (company) — Wholly-owned subsidiary being sold
- August 12, 2024 (date) — Date of report and announcement
- Fourth quarter of 2024 (date) — Expected closing period for the transaction
FAQ
What is the name of the subsidiary being sold?
The subsidiary being sold is Marker Therapeutics, LLC.
When is the transaction expected to close?
The transaction is expected to close in the fourth quarter of 2024.
What is the strategic reason for this sale?
The sale is part of Marker Therapeutics' strategic plan to focus on its T-cell therapies.
What are the conditions for closing the transaction?
The transaction is subject to customary closing conditions.
What is the filing date of this 8-K report?
The filing date of this 8-K report is August 12, 2024.
Filing Stats: 476 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-08-12 07:12:59
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar
- $2 million — nouncing that the Company was awarded a $2 million grant from the National Institutes of H
Filing Documents
- tm2421372d1_8k.htm (8-K) — 26KB
- tm2421372d1_ex99-1.htm (EX-99.1) — 16KB
- tm2421372d1_ex99-1img001.jpg (GRAPHIC) — 5KB
- 0001104659-24-088054.txt ( ) — 266KB
- mrkr-20240812.xsd (EX-101.SCH) — 3KB
- mrkr-20240812_def.xml (EX-101.DEF) — 26KB
- mrkr-20240812_lab.xml (EX-101.LAB) — 35KB
- mrkr-20240812_pre.xml (EX-101.PRE) — 24KB
- tm2421372d1_8k_htm.xml (XML) — 5KB
01. Other Information
Item 8.01. Other Information On August 12, 2024, Marker Therapeutics, Inc. (the "Company") issued a press release announcing that the Company was awarded a $2 million grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program to support the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma (NHL) who have relapsed following anti-CD19 chimeric antigen receptor (CAR) T cell therapy. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, dated August 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Marker Therapeutics, Inc. Dated: August 12, 2024 By: /s/ Juan Vera Juan Vera President and Chief Executive Officer